DAILY STOCK MARKET REPORT 28 March 2011
|
FTSE 100 |
5900.76, +19.89 |
Dow |
12220.59, +50.03 |
|
FTSE 250 |
11629.3, +23.8 |
Nasdaq |
2743.06, +6.64 |
|
FTSE All Share |
3065.83, +10.06 |
S&P 500 |
1313.8, +4.14 |
|
Nikkei |
9433.34, -102.79 |
Hang Seng |
23008.31, +150.36 |
|
Oil (Crude) |
$105.4, -$0.20 |
Gold |
$1426.20, -$8.70 |
|
Base Rate |
0.5% |
10 Yr Gilt |
3.65% |
|
£/$ |
1.597 |
£/€ |
1.135 |
|
1 month LIBOR |
0.617 |
3 month LIBOR |
0.815 |
Markets
New York - US indices advanced on Friday following positive corporate and economic news. The Dow Jones gained 50.03 points to 12,220.59, the S&P 500 added 4.14 points to 1,313.80 and the Nasdaq rose 6.64 points to 2,743.06.
The Commerce Department said the U.S. economy grew at a 3.1% annual rate in the fourth quarter, led by a jump in consumer spending that will be hard to match early in the year as energy prices surge. The revised increase in gross domestic product compares with a 2.8% estimate issued last month. Not all the data was positive, but investors chose to ignore the Thomson Reuters/University of Michigan final index of consumer sentiment which decreased to 67.5 from 77.5 in February. The preliminary estimate issued earlier this month was 68.2.
In corporate news, Oracle climbed 1.6% to $32.64 after the company forecast profit excluding acquisition costs and some other expenses of 69 cents to 73 cents this quarter, beating the average analyst estimate of 66 cents. Bristol-Myers Squibb rose 3.3% to $27.29 after winning U.S. approval for ipilimumab, the first drug in a new family of medicines to treat advanced melanoma, the most deadly form of skin cancer.
Tokyo - The Nikkei dropped 102.79 points to 9,433.34 this morning as radiation hampered efforts to cool crippled nuclear reactors in Japan. Tokyo Electric Power Co., the operator of the nuclear plant, tumbled 18% to its lowest since 1977. Acer Inc., the world’s second-largest computer maker, fell 6.9% in Taipei after saying first-quarter sales may miss expectations.
Hong Kong - The Hang Seng is currently 150.36 points lower at 23,008.31 after China Construction Bank Corp. and China Petroleum & Chemical Corp.’s profits missed analyst estimates. China Construction Bank, the world’s second-largest lender by market value, and China Petroleum & Chemical, Asia’s biggest refiner, dropped more than 2.5%. China Pacific Insurance (Group) Co., the nation’s third-largest insurer, climbed 2.1% after reporting results that beat estimates.
London - The FTSE 100 rose 19.89 points to 5,900.76 on Friday. Reckitt Benckiser jumped 3.1% to 3,160p after BofA Merrill Lynch raised its recommendation on the shares to “buy” from “neutral.” African Barrick Gold soared 1.9% to 539p as the company said it has found further gold deposits at its Nyanzaga project. Separately, Citigroup Inc. upgraded the shares to “buy” from “hold.”
Economics
US Personal income & spending (Feb) 13:30 BST/ 08:30 EDT
Analysts expect personal income to rise by 0.6%. Most of the boost to income from this year’s reduction in payroll taxes should have occurred in January, but there may be a further positive impact in February. Personal spending probably rose 0.8%, reflecting improved auto sales as well as higher gasoline and food prices. Based on the details of the latest CPI report, the February core PCE deflator is likely to rise 0.2%, with the y-o-y rate edging up to 0.9%.
US Pending home sales (Feb) 15:00 BST/ 10:00 EDT
Indications of housing demand over the past month have been discouraging. Sales of new homes fell to a multi-decade low in February, and applications for mortgages to purchase homes have remained at a subdued level.
Corporate
Pharmaceutical giant AstraZeneca PLC lifted its full-year earnings targets after reaching a settlement with the U.K. and U.S. tax authorities over transfer pricing arrangements. As a result of the agreements, the company’s effective tax rate is expected to be 6% lower than originally forecast and the group has thus raised its 2011 full year targets for core earnings per share, calculated before exceptional items, to between $6.90-$7.20 per share from $6.45-$6.75 guided previously. Transfer pricing refers to the pricing of assets, services and funds transferred within an organization. The accord with U.S. and U.K. authorities pertain to transfer pricing arrangements for AstraZeneca’s U.S. business for the 13-year period from 2002 to the end of 2014. AstraZeneca has regularly set aside funds for such disputes, and said it will release part of its provision to deal with the settlement, which will result in a $500 million benefit to first-quarter earnings. The company had previously guided for an effective tax rate of 27% in 2011, but now expects this to be 21%. The news gave AstraZeneca shares an early boost Monday and were up 1.1% or 32p at 2906p at 0808 GMT.
The above details are provided for information only and are not intended to be construed as solicitation for the sale or purchase of any particular investment nor as specific investment advice.
If you would like to discuss any aspect of financial planning or investment, one of the specialist advisors in Lupton Fawcett’s Asset Management Department would be delighted to help.
Posted: March 28th, 2011 under Asset Management.
Comments: none
